Deals

Based at DCU Invent, Deciphex has gained investors including Inova and GI Partners as it looks to refine its offering for the toxicologic and gastrointestinal segments of pathology.

Oxford Brain Diagnostics hopes to commercialise an early diagnosis tool for Alzheimer’s disease pioneered through eight years of University of Oxford research.

The follow-on investment complements $1.7m raised by Oxford data analytics spinout Mind Foundry in 2016 from investors including Oxford Sciences Innovation.

Building on Chiba and Hokkaido university research, Think-Lands is aiming to commercialise microneedles manufactured with its optical vortex production system.

Talaris, previously known as Regenerex and based on research at University of Louisville, will use the funding to advance its cell therapy into later-stage clinical development.

Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.

Stanford University has participated in a $46m funding round for Gen.G together with venture capital firms and celebrity investors such as actor Will Smith.

Gyroscope Therapeutics, spun out of Cambridge and Syncona, has merged with Orbit Biomedical to form a fully-integrated retinal gene therapy developer.